EPIX · ESSA Pharma
Acquired Company
XenoTherapeutics completed its acquisition of ESSA Pharma on 10/9/2025 for approximately $0.1242 per share, plus one contingent value right per share.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.
Market Cap
9.518M
52 Wk Range
$0.18 - $5.97
Previous Close
$0.20
Open
$0.20
Volume
N/A
Day Range
$0.20 - $0.20
Enterprise Value
-99.33M
Cash
109.6M
Avg Qtr Burn
-5.221M
Insider Ownership
5.62%
Institutional Own.
73.70%
Qtr Updated
Jun 30th 2025